Ad-hoc | 9 January 2012 21:14
WILEX AG / Key word(s): Capital Increase/Weiteres Schlagwort
09.01.2012 21:14
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz
(German Securities Trading Act)
- Not for distribution, publication or transmission
in the USA, Canada, Japan and Australia -
WILEX AG resolves rights issue using authorised capital
Munich, Germany, 09 January 2012. The Executive Management Board of WILEX
AG (ISIN DE0006614720/WL6/Frankfurt stock exchange) today resolved, with
the approval of the Supervisory Board, to increase the Company's share
capital using authorised capital from EUR 21,613,035.00 by up to EUR
3,201,928.00 to up to EUR 24,814,963.00 by issuing up to 3,201,928 new
no-par value bearer shares with a pro-rata interest in capital of EUR 1.00
each and full entitlement to dividends effective 1 December 2011 in return
for cash contributions.
Landesbank Baden-Württemberg, Stuttgart, Germany, will offer the new shares
to shareholders at a 27:4 ratio by means of an indirect subscription right.
Hence, shareholders will be entitled to subscribe for 4 new shares for each
27 existing shares held. One of the existing shareholders has undertaken to
waive its subscription rights with respect to 21 shares in order to ensure
an even subscription ratio.
The subscription period will begin on 17 January 2012 and is expected to
end on 30 January 2012. The subscription price is fixed at EUR 3.10. There
will be no organised trading in subscription rights.
Any new shares not subscribed for as a result of the offer may be purchased
by shareholders only - also at the subscription price - as part of an
additional subscription for shares. Binding offers for such additional
subscriptions must be submitted within the subscription period.
The new shares are to be admitted to trading in the regulated market on
Frankfurt stock exchange and in the Prime Standard (regulated market
segment that imposes further post-admission obligations) on the Frankfurt
stock exchange without the publication of an offering prospectus. Due to
the different dividend entitlement the new shares will be traded separately
with its own ISIN until the planned inclusion of the new shares in the
existing stock exchange listing (after the AGM). The new WILEX shares are
due to be listed on the Frankfurt stock exchange on 6 February 2012.
For further details on the rights issue, please see the subscription offer
provisionally planned to be published in the electronic Federal Gazette on
16 January 2012 and on the website of WILEX AG (www.wilex.com).
The main shareholders dievini Hopp BioTech holding GmbH & Co. KG,
Verwaltungsgesellschaft des Golfclubs St. Leon-Rot GmbH and UCB Pharma S.A
- whose current interest in the voting capital of WILEX AG total 58.7% -
have advised that they intend to exercise at least their subscription
rights.
WILEX AG plans to use the gross proceeds of approx. EUR 10 million from the
rights issue to finance its ongoing clinical studies and further growth as
well as to enhance its equity.
Important notes
This ad hoc release does not constitute either an offer to sell or an
invitation to buy securities. In particular, this document does not
constitute an offer to sell securities or a solicitation of an offer to buy
securities in the United States of America. The shares of WILEX AG (the
'Shares') may not be offered or sold in the United States of America or to
or for the account or benefit of 'U.S. persons' (as defined in Regulation S
under the U.S. Securities Act of 1933, as amended (the 'Securities Act')),
unless they have been registered or are exempt from registration under the
Securities Act. The Shares have not been and will not be registered under
the Securities Act. There will be no public offer of Shares in the United
States of America.
+++ End of ad-hoc release +++
---------------------------------------------------------------------------
Information and Explaination of the Issuer to this News:
About WILEX AG
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the company has a broad portfolio of near-to-market
therapeutic and diagnostic products for the targeted treatment and specific
detection of various types of cancer. The company's therapeutic product
candidates are based on antibodies and small molecules. Through its US
subsidiary WILEX Inc. in Cambridge, MA, WILEX markets a portfolio of
research use only and in vitro diagnostic tests under the brand Oncogene
Science. These diagnostic tests could be developed as companion diagnostics
in clinical trials and for therapy monitoring. The wholly owned subsidiary
Heidelberg Pharma GmbH gives WILEX access to an attractive and highly
promising antibody drug conjugate technology platform and a pre-clinical
service business. The business model of WILEX covers the entire value chain
in the oncology market and comprises research, technology, development
collaboration as well as sales and marketing. WILEX's customers and
partners include leading international pharmaceutical companies. ISIN
DE0006614720 / WKN 661472 / Symbol WL6
Contact
WILEX AG
Corporate Communications
Katja Arnold (CIRO)
Grillparzerstr. 10
81675 Munich; Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-mail: investors@wilex.com
This communication contains certain forward-looking statements, relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by
general discussion of strategy, plans or intentions of the Company. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial condition, performance, or achievements, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, prospective investors and partners are cautioned not
to place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments. Given these uncertainties, prospective investors
and partners are cautioned not to place undue reliance on such
forward-looking statements. We disclaim any obligation to update any such
forward-looking statements to reflect future events or developments.
09.01.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------